#abval18

3rd International

Antibody Validation Meeting

  • University of Bath
  • 16/09/21 - 17/09/21
  • 14 Speakers

In September of 2018 we had the pleasure of welcoming delegates to the Third International Antibody Validation Meeting.

The meeting, which attracted 110 delegates from Europe, the US and Asia, was organised by the University of Bath, and supported by AstraZeneca and CiteAb. It built on the successful format of the previous meeting which was held in September 2016 as part of the University 50th celebrations.

Selected photos

  • Deepa Shankar (Thermo Fisher Scientific)
  • Camilla alongside her poster
  • The audience
  • The CiteAb team

You can see all of the photos from the event on our Facebook page.

The talks

Mathias Uhlén
Mathias Uhlén (Royal Institute of Technology, KTH): Enhanced validation of antibodies for research applications.
Birte Aggeler
Birte Aggeler (Bio-Techne/R&D Systems): Antibody Validation: New Tools, scientific thinking and common sense.
Kathryn Lilley
Kathryn Lilley (University of Cambridge): Probing the spatial proteome.
Deepa Shankar
Deepa Shankar (Thermo Fisher Scientific): Nailing it with Thermo Fisher Scientific's antibody validation toolbox!
Video unavailable
Richard Goodwin (AstraZeneca): Imaging mass cytometry and multimodal mass spectrometry imaging combined to define drug delivery, metabolism and response.
Alejandra Solache
Alejandra Solache (Abcam): Advances in antibody validation and development.
Jan Roger
Jan Roger (GSK): The approaches GSK are using to ensure antibodies are fit for purpose for target identification/validation.
Jason Li
Jason Li (Proteintech): The role of antigens in antibody validation.
Roberto Polakiewicz
Roberto Polakiewicz (Cell Signaling Technology): The science behind antibody validation at Cell Signaling Technology.
Fridtjof Lund-Johansen
Fridtjof Lund-Johansen (Oslo University Hospital): Array-based antibody validation.
Dagmar Ehrnhoefer
Dagmar Ehrnhoefer (BioMed X): Validation of post-translational modification specific antibodies for non-histone proteins.
Peter Kloehn
Peter Kloehn (MRC Prion Unit at UCL): Identifying antibodies against cryptic antigens on the ectodomain of cancer targets.
Video unavailable
Gemma Jones (Astra Zeneca): Validation of clinical IHC biomarker assays for translational science.

More talks will be uploaded as they become available.